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Materials and Methods: 
Fmoc-Orn(Boc)-OH, HBTU, HOBt and N-iodosuccinimide were bought from Chem-Impex 
International, Inc. Fluoroacetonitrile was purchased from Reagent World, Inc. 3-iodosalicylic 
acid and 4-fluoro-2-hydroxy-3,5-diiodobenzoic acid were obtained from Enamine and Aurum 
Pharmatech, respectively. Methyl 4-bromo-2-hydroxybenzoate was bought from Ark Pharm. 
Salicylic acid, 3,5-diiodosalicylic acid, 3,5-dibromosalicylic acid, 3,5-dichlorosalicylic acid, 
3,5-isopropylsalicylic acid, 5-iodosalicylic acid, 3,5-diiodobenzoic acid, DIPEA, anhydrous 
methanol, anhydrous DMF, anhydrous dichloromethane, piperidine, triethylamine, 
trifluoroacetic acid, chloroacetonitrile and HPLC-grade acetonitrile were purchased from 
Sigma-Aldrich. TCEP, streptavidin agarose beads (catalogue no. 20353) and Halt protease 
inhibitor cocktail (EDTA-free) were obtained from Thermo Scientific. Precoated silica gel 
plates were bought from Merck. Deuterated solvents were purchased from Cambridge Isotope 
Laboratories. Plasmid purification kit was bought from Bio Basic Canada Inc. Rabbit 
polyclonal anti-PAD1 (catalogue no. ab181762), mouse monoclonal anti-histone H3 
(catalogue no. ab10799) and rabbit polyclonal anti-H3 (Citrulline R2, R8 and R17) (catalogue 
no. ab5103) were obtained from Abcam. 1H and 13C NMR spectra were recorded in d4-MeOH 
or d6-DMSO as solvent using a Bruker 500 MHz NMR spectrometer. Chemical shift values 
are cited with respect to SiMe4 (TMS) as the internal standard. Column chromatography was 
performed in glass columns. All the inhibitors and probes (compounds 1-22) were purified by 
reverse-phase HPLC using a semi-preparative C18 column (Agilent, 21.2 × 250 mm, 10 µm) 
and a water/acetonitrile gradient supplemented with 0.05% trifluoroacetic acid. Fluorographs 
were recorded using a Typhoon scanner with excitation/emission maxima of ∼546/579, 





Synthesis of 25. 
 
Compound 25 was synthesized as reported earlier with minor modifications.[2] Briefly, 
diisopropyl ethylamine (DIPEA) (1.2 mL, 6.6 mmol), HBTU (1.3 g, 3.3 mmol) and HOBt 
(297 mg, 2.2 mmol) were added sequentially to a solution of Fmoc-Orn(Boc)-OH (1 g, 2.2 
mmol) and 1,2-phenylenediamine (238 mg, 2.2 mmol) in anhydrous dimethylformamide 
(DMF) and the mixture was stirred for 4 h at 25 ⁰C under nitrogen atmosphere. Then the 
reaction mixture was poured into water to precipitate compound 23 and it was recovered by 
vacuum filtration, washed with water and dried in vacuo. Crude 23 was then dissolved in 
glacial acetic acid (20 mL) and was refluxed for 4 h. Then the mixture was evaporated in 
vacuo to afford a gummy brown liquid which was poured into brine, neutralized with sodium 
bicarbonate and extracted with excess dichloromethane. The organic extract was washed 
thoroughly with water, brine, dried over anhydrous sodium sulphate and concentrated in 
vacuo to afford compound 24. Compound 24 was treated with 1:4 piperidine/DMF (v/v) for 
30 min to remove the Fmoc-group and the mixture was vigorously stirred with excess 
hexane. The hexane layer was decanted off and this procedure was repeated for several times 
until most of the DMF was removed. Fmoc-removal afforded compound 25 as gummy brown 





Synthesis of 27. 
 
Methyl iodide (0.18 mL, 2.9 mmol) was added dropwise to a suspension of 3,5-
diiodosalicylic acid (DISA) (0.5 g, 1.3 mmol) and potassium carbonate (0.45 g, 3.3 mmol) in 
anhydrous DMF. The mixture was heated in a sealed tube at 90 ⁰C for 12 h followed by 
pouring into water to precipitate compound 26, which was recovered by vacuum filtration, 
washed with water and dried in vacuo. Crude compound 26 (0.22 g, 0.53 mmol) was then 
dissolved in 1:1 THF/MeOH (10 mL) and was treated with 1 M aqueous lithium hydroxide 
solution (5.3 mL). The mixture was allowed to stir for 2 h at 25 ⁰C and the organic solvents 
were removed under reduced pressure. The mixture was then acidified with 2 M aqueous 
hydrochloric acid and was extracted twice with excess diethyl ether. The combined ether 
extracts were washed with water, dried over anhydrous sodium sulphate and concentrated in 
vacuo to afford 27 as an off-white solid. Crude 27 was purified by column chromatography 
using hexane/ethyl acetate as the eluent and was characterized by 1H, 13C NMR spectroscopy 
and mass spectrometry. Overall yield: 60%. 1H NMR (DMSO-d6) δ (ppm): 13.4 (s, 1H), 8.3 
(s, 1H), 7.95 (s, 1H), 3.76 (s, 3H); 13C NMR (DMSO-d6) δ (ppm): 165.6, 158.6, 149.7, 139.7, 







Synthesis of 30. 
 
Deoxygenated triethylamine (20 mL) and trimethylsilyl acetylene (TMSA) (2.4 mL, 17.3 mmol) 
was added to methyl 4-bromo-2-hydroxy benzoate (1g, 4.3 mmol), Pd(PPh3)2Cl2 (304 mg, 0.4 
mmol) and copper (I) iodide (83 mg, 0.4 mmol), and the mixture was refluxed for 12 h under 
nitrogen atmosphere. Excess triethylamine was evaporated under reduced pressure and 
residue was resuspended in water. Then the dark brown mixture was extracted several times 
with excess dichloromethane and the combined dichloromethane extracts were filtered under 
vacuum, washed with water and brine, dried over anhydrous sodium sulphate and 
concentrated in vacuo to yield a dark brown gummy liquid. 28 was purified from this crude 
mixture by column chromatography using hexane/ethyl acetate as eluent and was 
characterized by 1H NMR spectroscopy and mass spectrometry. Yield: 70%. 1H NMR 
(CDCl3) δ (ppm): 10.53 (s, 1H), 7.57 (d, J = 10 Hz, 1H), 6.88 (d, J = 1.5 Hz, 1H), 6.77 (dd, J 
= 8.2 Hz, 1H), 3.76 (s, 3H), 0.07 (s, 9H); ESI-MS (m/z) calculated for C13H16O3Si [M + H]+: 
249.09, found 249.2. Compound 28 (0.5 g, 2.0 mmol) was dissolved in 1:1 THF/MeOH (10 
mL) and was treated with a 1 M aqueous solution of lithium hydroxide (20 mL). The mixture 
was stirred at room temperature for 2 h and the organic solvents were evaporated under 
reduced pressure followed by acidification with 1 M hydrochloric acid. The mixture was then 
extracted twice with excess diethyl ether and the combined organic extract was washed with 
water, dried over anhydrous sodium sulphate and concentrated in vacuo. Compound 29 was 
purified from the crude mixture by column chromatography using hexane/ethyl acetate as 
mobile phase and was characterized by 1H NMR spectroscopy and mass spectrometry. Yield: 
90%. 1H NMR (CDCl3) δ (ppm): 7.77 (d, J = 8.2 Hz, 1H), 7.04 (d, J = 1.2 Hz, 1H), 6.93 (dd, 
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J = 8.2 Hz, 1H), 3.16 (s, 1H); ESI-MS (m/z) calculated for C9H6O3 [M + H]+: 163.04, found 
163.2. N-iodosuccinimide (417 mg, 1.9 mmol) was added to a solution of 29 (100 mg, 0.6 
mmol) in acetonitrile (ACN) (15 mL) and the mixture was heated at 80 ⁰C in a sealed tube 
for 4 h. Excess acetonitrile was then evaporated under reduced pressure and the residue was 
resuspended in dichloromethane, washed with water, dried over anhydrous sodium sulphate 
and concentrated in vacuo to yield 30 as off-white solid. 30 was purified from the crude 
mixture by column chromatography using hexane/ethyl acetate as the eluent and was 
characterized by 1H NMR spectroscopy and mass spectrometry. Yield: 78%. 1H NMR 
(DMSO-d6) δ (ppm): 8.07 (s, 1H), 4.87 (s, 1H); ESI-MS (m/z) calculated for C9H4I2O3 [M + 
H]+: 414.83, found 414.8. 

















Compound 25, HBTU, HOBt,
DIPEA, DMF, 25 0C, 12 h
i. SOCl2, DCM, DMF, 60
0C, 6 h
























Compounds 1-22 were synthesized following three steps. In the first step, compound 25 was 
coupled with commercially available carboxylic acids or compound 27 (for compounds 3 and 
4) or compound 30 (for compounds 21 and 22) by following either of the two pathways (Path 
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A or Path B) to afford amides with Boc-protected ornithine side chain. In the second step, the 
Boc-protecting group was removed from the ornithine side chain to produce the free amine. 
The haloacetamidine warhead was then installed in the third step using an ethyl 
haloacetimidate hydrochloride. General procedures for these three steps are given below. 
General Procedure for Path A. 
DIPEA (3 eq), HBTU (2 eq) and HOBt (2 eq) were added sequentially to a solution of 
carboxylic acid (1 eq) and compound 25 (1 eq) in anhydrous DMF. The mixture was allowed 
to stir at room temperature for 12 h under a nitrogen atmosphere. Then the reaction mixture 
was poured into water to precipitate the desired amide, which was recovered by vacuum 
filtration, washed with water and dried in vacuo. The amide was used in the subsequent step 
without further purification. 
General Procedure for Path B. 
Thionyl chloride (3 eq) was added dropwise to a suspension of carboxylic acid (1 eq) in 
anhydrous dichloromethane with vigorous stirring. Then a catalytic amount of DMF (100 µL 
for 1 g of carboxylic acid) was added and the reaction mixture was refluxed for 6 h. The 
organic solvent and excess thionyl chloride were evaporated under reduced pressure to afford 
the acyl chloride. Triethylamine (5 eq) was added to a suspension of compound 25 (1 eq) and 
acyl chloride (2 eq) in THF, and the resulting precipitate was dissolved by dropwise addition 
of water. The mixture was allowed to stir at room temperature for 12 h. THF was evaporated 
under reduced pressure and the residue was extracted twice with dichloromethane. The 
combined organic extract was washed with water, dried over anhydrous sodium sulphate and 




General Procedure for Boc-deprotection and warhead installation. 
A Boc-protected compound was dissolved in 1:4 trifluoroacetic acid/dichloromethane (v/v) 
(10 mL for 1 g of Boc-protected compound) and the mixture was stirred at room temperature 
for 1 h. Excess trifluoroacetic acid/dichloromethane was evaporated under reduced pressure 
to afford the free amine as a gummy liquid. Triethylamine (4 eq) and ethyl haloacetimidate 
hydrochloride (2 eq) were added sequentially to a solution of free amine (1 eq) in anhydrous 
methanol. The mixture was allowed to stir at room temperature for 4 h. Methanol and excess 
triethylamine were evaporated under reduced pressure. Compounds 1-22 were then purified 
as trifluoroacetate salts by reverse phase HPLC using a pre-packed C18 column and a 
water/acetonitrile (supplemented with 0.05% TFA) gradient as the eluent. 
Compounds 1-22 were thoroughly characterized by 1H and 13C NMR spectroscopy and mass 
spectrometry. These data are given in Figures S14-S57. The purity of compounds 1-22 was 
determined by 1H NMR spectroscopy and LC-MS analysis. All the tested compounds were 
≥95% pure. 
Compound 1. This compound was synthesized from commercially available 3,5-
diiodosalicylic acid following Path B. Yield: 32% over three steps. 1H NMR (CD3OD) δ 
(ppm): 8.18 (d, J = 2 Hz, 1H), 8.13 (d, J = 2 Hz, 1H), 7.62-7.64 (m, 2H), 7.41-7.43 (m, 2H), 
5.55-5.58 (m, 1H), 5.21 (s, 1H), 5.12 (s, 1H), 3.37 (t, J = 7.3 Hz, 2H), 2.25-2.32 (m, 1H), 
2.16-2.24 (m, 1H), 1.80-1.88 (m, 1H), 1.71-1.79 (m, 1H); 13C NMR (CD3OD) δ (ppm): 
169.3, 163.1, 163.0, 161.2, 160.9, 160.1, 153.2, 151.0, 135.8, 133.0, 125.3, 115.7, 113.9, 
86.9, 79.6, 78.3, 76.9, 41.4, 28.9, 23.7; ESI-MS (m/z) calculated for C20H20N5O2F1I2 [M + 
H]+: 635.97, found 636.0. 
Compound 2. This compound was synthesized from commercially available 3,5-
diiodosalicylic acid following Path B. Yield: 26% over three steps. 1H NMR (CD3OD) δ 
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(ppm): 8.16 (d, J = 2 Hz, 1H), 8.13 (d, J = 2 Hz, 1H), 7.59-7.62 (m, 2H), 7.37-7.40 (m, 2H), 
5.53-5.56 (m, 1H), 4.27 (s, 2H), 3.33-3.36 (m, 2H), 2.25-2.32 (m, 1H), 2.14-2.22 (m, 1H), 
1.80-1.86 (m, 1H), 1.71-1.78 (m, 1H); 13C NMR (CD3OD) δ (ppm): 169.4, 163.4, 161.6, 
161.3, 160.1, 153.1, 151.0, 135.8, 132.7, 125.5, 115.6, 113.9, 86.9, 79.6, 53.4, 41.9, 38.7, 
28.9, 23.6; ESI-MS (m/z) calculated for C20H20N5O2Cl1I2 [M + H]+: 651.95, found 652.0. 
Compound 3. This compound was synthesized from compound 27 following Path B. Yield: 
35% over three steps. 1H NMR (CD3OD) δ (ppm): 8.19 (d, J = 2.2 Hz, 1H), 7.89 (d, J = 2.2 
Hz, 1H), 7.65-7.67 (m, 2H), 7.43-7.45 (m, 2H), 5.47 (t, J = 6.8 Hz, 1H), 5.22 (s, 1H), 5.13 (s, 
1H), 3.67 (s, 3H), 3.36-3.4 (m, 2H), 2.17-2.22 (m, 2H), 1.83-1.93 (m, 1H), 1.70-1.78 (m, 1H); 
13C NMR (CD3OD) δ (ppm): 165.7, 163.2, 163.0, 161.5, 161.3, 157.5, 153.2, 149.8, 138.7, 
132.7, 130.4, 125.5, 113.9, 93.4, 87.8, 78.3, 76.9, 61.7, 41.3, 29.3, 23.7; ESI-MS (m/z) 
calculated for C21H22N5O2F1I2 [M + H]+: 649.99, found 649.8. 
Compound 4. This compound was synthesized from compound 27 following Path B. Yield: 
29% over three steps. 1H NMR (CD3OD) δ (ppm): 8.20 (d, J = 2.2 Hz, 1H), 7.90 (d, J = 2.2 
Hz, 1H), 7.63-7.66 (m, 2H), 7.40-7.44 (m, 2H), 5.44-5.48 (m, 1H), 4.28 (s, 2H), 3.68 (s, 3H), 
3.34-3.37 (m, 2H), 2.17-2.22 (m, 2H), 1.83-1.91 (m, 1H), 1.70-1.78 (m, 1H); 13C NMR 
(CD3OD) δ (ppm): 165.7, 163.4, 161.5, 161.2, 157.5, 153.2, 149.8, 138.7, 133.0, 130.4, 
125.3, 114.0, 93.4, 87.8, 61.7, 41.9, 38.7, 29.3, 23.6; ESI-MS (m/z) calculated for 
C21H22N5O2Cl1I2 [M + H]+: 665.96, found 665.8. 
Compound 5. This compound was synthesized from commercially available 3,5-
diiodobenzoic acid following Path A. Yield: 37% over three steps. 1H NMR (CD3OD) δ 
(ppm): 8.19-8.21 (m, 3H), 7.65-7.67 (m, 2H), 7.45-7.47 (m, 2H), 5.48-5.51 (m, 1H), 5.21 (s, 
1H), 5.12 (s, 1H), 3.35-3.39 (m, 2H), 2.19-2.25 (m, 2H), 1.81-1.89 (m, 1H), 1.70-1.77 (m, 
1H); 13C NMR (CD3OD) δ (ppm): 165.8, 163.1, 163.0, 161.9, 161.6, 161.4, 161.1, 153.5, 
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148.4, 136.1, 135.8, 131.7, 125.9, 113.8, 94.0, 78.3, 76.9, 41.3, 29.1, 23.7; ESI-MS (m/z) 
calculated for C20H20N5O1F1I2 [M + H]+: 619.98, found 620.0. 
Compound 6. This compound was synthesized from commercially available 3,5-
diiodobenzoic acid following Path A. Yield: 32% over three steps. 1H NMR (CD3OD) δ 
(ppm): 8.19-8.21 (m, 3H), 7.65-7.67 (m, 2H), 7.45-7.47 (m, 2H), 5.48-5.51 (m, 1H), 4.28 (s, 
2H), 3.33-3.36 (m, 2H), 2.17-2.27 (m, 2H), 1.82-1.88 (m, 1H), 1.70-1.77 (m, 1H); 13C NMR 
(CD3OD) δ (ppm): 165.8, 163.4, 161.8, 161.6, 161.3, 161.0, 153.5, 148.4, 136.1, 135.8, 
131.8, 125.9, 113.8, 94.1, 41.9, 38.7, 29.0, 23.6; ESI-MS (m/z) calculated for 
C20H20N5O1Cl1I2 [M + H]+: 635.95, found 636.0. 
Compound 7. This compound was synthesized from commercially available salicylic acid 
following Path A. Yield: 33% over three steps. 1H NMR (CD3OD) δ (ppm): 7.81 (dd, J = 7.9 
Hz, 1H), 7.64-7.65 (m, 2H), 7.44-7.45 (m, 2H), 7.33-7.36 (m, 1H), 6.84-6.87 (m, 2H), 5.54-
5.57 (m, 1H), 5.21 (s, 1H), 5.11 (s, 1H), 3.35-3.41 (m, 2H), 2.23-2.28 (m, 2H), 1.83-1.93 (m, 
1H), 1.72-1.80 (m, 1H); 13C NMR (CD3OD) δ (ppm): 169.4, 163.1, 163.0, 159.3, 153.9, 
134.0, 130.5, 128.6, 127.6, 124.7, 119.1, 117.0, 115.5, 114.0, 78.3, 76.8, 41.4, 29.4, 23.7; 
ESI-MS (m/z) calculated for C20H22N5O2F1 [M + H]+: 384.18, found 384.4. 
Compound 8. This compound was synthesized from commercially available salicylic acid 
following Path A. Yield: 29% over three steps. 1H NMR (CD3OD) δ (ppm): 7.81 (dd, J = 8 
Hz, 1H), 7.62-7.64 (m, 2H), 7.42-7.43 (m, 2H), 7.32-7.36 (m, 1H), 6.83-6.87 (m, 2H), 5.53-
5.56 (m, 1H), 4.27 (s, 2H), 3.34-3.38 (m, 2H), 2.23-2.29 (m, 2H), 1.82-1.90 (m, 1H), 1.72-
1.80 (m, 1H); 13C NMR (CD3OD) δ (ppm): 169.4, 163.4, 159.3, 153.9, 134.2, 134.0, 130.5, 
128.5, 127.6, 124.5, 119.1, 117.0, 115.5, 114.0, 42.0, 38.7, 37.5, 29.5, 23.6; ESI-MS (m/z) 
calculated for C20H22N5O2Cl1 [M + H]+: 400.15, found 400.4. 
11 
 
Compound 9. This compound was synthesized from commercially available 3,5-
diisopropylsalicylic acid following Path B. Yield: 35% over three steps. 1H NMR (CD3OD) δ 
(ppm): 7.66-7.69 (m, 2H), 7.51 (d, J = 2.1 Hz, 1H), 7.47-7.52 (m, 2H), 7.18 (d, J = 2.1 Hz, 
1H), 5.59-5.62 (m, 1H), 5.21 (s, 1H), 5.12 (s, 1H), 3.37-3.40 (m, 2H), 2.76-2.81 (m, 2H), 
2.25-2.31 (m, 2H), 1.87-1.92 (m, 1H), 1.73-1.80 (m, 1H), 1.18-1.24 (m, 1H), 1.15 (d, J = 7 
Hz, 6H), 1.10-1.12 (m, 6H); 13C NMR (CD3OD) δ (ppm): 172.0, 163.5, 163.1, 163.0, 161.6, 
161.3, 161.1, 160.8, 157.1, 153.7, 138.8, 136.8, 131.5, 129.4, 126.0, 121.6, 112.3, 78.3, 76.8, 
41.4, 33.7, 28.7, 26.5, 23.8, 23.2, 23.1, 21.4; ESI-MS (m/z) calculated for C26H34N5O2F1 [M 
+ H]+: 468.28, found 468.4. 
Compound 10. This compound was synthesized from commercially available 3,5-
diisopropylsalicylic acid following Path B. Yield: 30% over three steps. 1H NMR (CD3OD) δ 
(ppm): 7.65-7.67 (m, 2H), 7.50 (d, J = 2.1 Hz, 1H), 7.45-7.47 (m, 2H), 7.19 (d, J = 2.1 Hz, 
1H), 5.60 (t, J = 7.5 Hz, 1H), 4.27 (s, 2H), 3.34-3.38 (m, 2H), 2.75-2.81 (m, 1H), 2.26-2.31 
(m, 2H), 1.84-1.93 (m, 1H), 1.73-1.80 (m, 1H), 1.19-1.23 (m, 1H), 1.15 (d, J = 6.9 Hz, 6H), 
1.10-1.12 (m, 6H); 13C NMR (CD3OD) δ (ppm): 171.9, 163.4, 161.8, 161.5, 161.2, 160.9, 
157.1, 153.7, 138.8, 136.8, 132.0, 129.3, 125.8, 121.6, 113.8, 112.4, 46.8, 41.9, 38.7, 33.7, 
28.8, 26.5, 23.7, 23.2, 23.1, 21.4; ESI-MS (m/z) calculated for C26H34N5O2Cl1 [M + H]+: 
484.25, found 484.4. 
Compound 11. This compound was synthesized from commercially available 3,5-
dibromosalicylic acid following Path B. Yield: 34% over three steps. 1H NMR (CD3OD) δ 
(ppm): 8.04 (d, J = 2.3 Hz, 2H), 7.79 (d, J = 2.3 Hz, 1H), 7.64-7.66 (m, 2H), 7.43-7.45 (m, 
2H), 5.56-5.59 (m, 1H), 5.21 (s, 1H), 5.12 (s, 1H), 3.37 (t, J = 7.3 Hz, 2H), 2.19-2.30 (m, 
2H), 1.82-1.89 (m, 1H), 1.73-1.79 (m, 1H); 13C NMR (CD3OD) δ (ppm): 169.4, 163.1, 163.0, 
162.0, 161.7, 161.4, 161.1, 157.1, 153.1, 139.4, 132.3, 129.3, 125.7, 116.3, 113.8, 112.3, 
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110.0, 78.3, 76.8, 41.3, 28.9, 23.7; ESI-MS (m/z) calculated for C20H20N5O2F1Br2 [M + H]+: 
540.00, found 541.8. 
Compound 12. This compound was synthesized from commercially available 3,5-
dibromosalicylic acid following Path B. Yield: 30% over three steps. 1H NMR (CD3OD) δ 
(ppm): 8.04 (d, J = 2.3 Hz, 2H), 7.80 (d, J = 2.3 Hz, 1H), 7.64-7.66 (m, 2H), 7.43-7.45 (m, 
2H), 5.56-5.59 (m, 1H), 4.27 (s, 2H), 3.33-3.36 (m, 2H), 2.18-2.32 (m, 2H), 1.82-1.89 (m, 
1H), 1.72-1.79 (m, 1H); 13C NMR (CD3OD) δ (ppm): 169.3, 163.4, 161.8, 161.6, 161.3, 
161.0, 157.1, 153.1, 139.4, 132.5, 129.3, 125.6, 116.3, 113.9, 112.4, 110.0, 41.9, 38.7, 28.9, 
23.6; ESI-MS (m/z) calculated for C20H20N5O2Cl1Br2 [M + H]+: 555.97, found 557.8. 
Compound 13. This compound was synthesized from commercially available 3,5-
dichlorosalicylic acid following Path B. Yield: 36% over three steps. 1H NMR (CD3OD) δ 
(ppm): 7.87 (d, J = 2.5 Hz, 2H), 7.65-7.67 (m, 2H), 7.53 (d, J = 2.5 Hz, 1H), 7.45-7.46 (m, 
2H), 5.56-5.59 (m, 1H), 5.21 (s, 1H), 5.12 (s, 1H), 3.38 (t, J = 7.2 Hz, 2H), 2.21-2.31 (m, 
2H), 1.84-1.90 (m, 1H), 1.72-1.79 (m, 1H); 13C NMR (CD3OD) δ (ppm): 169.2, 163.1, 163.0, 
161.5, 161.2, 155.5, 153.1, 133.7, 132.1, 125.9, 125.8, 123.3, 123.2, 116.3, 113.8, 78.3, 76.8, 
41.3, 28.9, 23.7; ESI-MS (m/z) calculated for C20H20N5O2F1Cl2 [M + H]+: 452.11, found 
452.0. 
Compound 14. This compound was synthesized from commercially available 3,5-
dichlorosalicylic acid following Path B. Yield: 31% over three steps. 1H NMR (CD3OD) δ 
(ppm): 7.86 (d, J = 2.5 Hz, 2H), 7.64-7.66 (m, 2H), 7.53 (d, J = 2.5 Hz, 1H), 7.43-7.45 (m, 
2H), 5.56-5.59 (m, 1H), 4.27 (s, 2H), 3.34-3.37 (m, 2H), 2.21-2.31 (m, 2H), 1.84-1.88 (m, 
1H), 1.73-1.78 (m, 1H); 13C NMR (CD3OD) δ (ppm): 169.2, 163.4, 161.9, 161.6, 161.3, 
155.5, 153.1, 133.6, 132.4, 125.9, 125.6, 123.3, 123.2, 116.4, 113.9, 41.9, 38.7, 29.0, 23.6; 
ESI-MS (m/z) calculated for C20H20N5O2Cl3 [M + H]+: 468.08, found 468.0. 
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Compound 15. This compound was synthesized from commercially available 5-iodosalicylic 
acid following Path B. Yield: 32% over three steps. 1H NMR (CD3OD) δ (ppm): 8.14 (d, J = 
2.2 Hz, 1H), 7.65-7.66 (m, 2H), 7.61 (dd, J = 8.7 Hz, 1H), 7.45-7.47 (m, 2H), 6.70 (d, J = 8.7 
Hz, 1H), 5.54-5.57 (m, 1H), 5.21 (s, 1H), 5.12 (s, 1H), 3.35-3.40 (m, 2H), 2.20-2.29 (m, 2H), 
1.82-1.89 (m, 1H), 1.71-1.79 (m, 1H); 13C NMR (CD3OD) δ (ppm): 168.1, 163.1, 163.0, 
161.5, 161.2, 159.0, 153.6, 142.6, 137.3, 132.1, 125.7, 119.4, 117.8, 113.8, 79.7, 78.3, 76.8, 
46.5, 41.3, 29.0, 23.7; ESI-MS (m/z) calculated for C20H21N5O2F1I1 [M + H]+: 510.08, found 
510.2. 
Compound 16. This compound was synthesized from commercially available 5-iodosalicylic 
acid following Path B. Yield: 26% over three steps. 1H NMR (CD3OD) δ (ppm): 8.14 (d, J = 
2.2 Hz, 1H), 7.60-7.63 (m, 3H), 7.41-7.42 (m, 2H), 6.69 (d, J = 8.7 Hz, 1H), 5.52-5.55 (m, 
1H), 4.27 (s, 2H), 3.33-3.37 (m, 2H), 2.19-2.29 (m, 2H), 1.80-1.88 (m, 1H), 1.71-1.78 (m, 
1H); 13C NMR (CD3OD) δ (ppm): 168.0, 163.4, 161.2, 158.9, 153.6, 142.5, 137.3, 132.9, 
125.3, 119.4, 117.9, 113.9, 79.7, 41.9, 38.7, 29.2, 23.6; ESI-MS (m/z) calculated for 
C20H21N5O2Cl1I1 [M + H]+: 526.05, found 526.2. 
Compound 17. This compound was synthesized from commercially available 3-iodosalicylic 
acid following Path A. Yield: 31% over three steps. 1H NMR (CD3OD) δ (ppm): 7.82-7.87 
(m, 2H), 7.62-7.66 (m, 2H), 7.42-7.45 (m, 2H), 6.64 (t, J = 7.9 Hz, 1H), 5.57-5.60 (m, 1H), 
5.21 (s, 1H), 5.12 (s, 1H), 3.36-3.39 (m, 2H), 2.19-2.32 (m, 2H), 1.82-1.89 (m, 1H), 1.72-
1.79 (m, 1H); 13C NMR (CD3OD) δ (ppm): 170.6, 163.1, 163.0, 161.9, 161.6, 161.3, 160.2, 
153.4, 144.1, 132.6, 127.2, 125.5, 120.2, 113.9, 113.9, 85.3, 78.3, 76.8, 41.4, 28.9, 23.7; ESI-
MS (m/z) calculated for C20H21N5O2F1I1 [M + H]+: 510.08, found 510.0. 
Compound 18. This compound was synthesized from commercially available 3-iodosalicylic 
acid following Path A. Yield: 25% over three steps. 1H NMR (CD3OD) δ (ppm): 7.82-7.86 
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(m, 2H), 7.63-7.64 (m, 2H), 7.41-7.43 (m, 2H), 6.64 (t, J = 7.9 Hz, 1H), 5.57-5.60 (m, 1H), 
4.27 (s, 1H), 3.33-3.37 (m, 2H), 2.20-2.32 (m, 2H), 1.82-1.89 (m, 1H), 1.72-1.79 (m, 1H); 
13C NMR (CD3OD) δ (ppm): 170.6, 163.4, 160.2, 153.3, 144.1, 132.8, 127.2, 125.4, 120.2, 
113.9, 113.9, 85.3, 41.9, 38.7, 28.9, 23.6; ESI-MS (m/z) calculated for C20H21N5O2Cl1I1 [M + 
H]+: 526.05, found 526.0. 
Compound 19. This compound was synthesized from commercially available 4-Fluoro-2-
hydroxy-3,5-diiodobenzoic acid following Path B. Yield: 34% over three steps. 1H NMR 
(CD3OD) δ (ppm): 8.33 (d, J = 6.9 Hz, 1H), 7.62-7.64 (m, 2H), 7.41-7.43 (m, 2H), 5.55-5.58 
(m, 1H), 5.21 (s, 1H), 5.12 (s, 1H), 3.37 (t, J = 7.3 Hz, 2H), 2.18-2.30 (m, 2H), 1.82-1.89 (m, 
1H), 1.71-1.77 (m, 1H); 13C NMR (CD3OD) δ (ppm): 169.0, 165.0, 163.3, 163.2, 163.1, 
163.0, 153.2, 137.7, 137.7, 133.0, 125.0, 113.9, 112.3, 78.3, 76.8, 73.3, 73.0, 66.2, 66.0, 41.4, 
29.0, 23.7, 21.7; ESI-MS (m/z) calculated for C20H19N5O2F2I2 [M + H]+: 653.97, found 
653.6. 
Compound 20. This compound was synthesized from commercially available 4-Fluoro-2-
hydroxy-3,5-diiodobenzoic acid following Path B. Yield: 28% over three steps. 1H NMR 
(CD3OD) δ (ppm): 8.34 (d, J = 6.9 Hz, 1H), 7.64-7.66 (m, 2H), 7.44-7.46 (m, 2H), 5.57-5.60 
(m, 1H), 4.27 (s, 1H), 3.31-3.36 (m, 2H), 2.22-2.30 (m, 2H), 1.83-1.89 (m, 1H), 1.72-1.78 
(m, 1H); 13C NMR (CD3OD) δ (ppm): 169.1, 165.0, 163.4, 163.2, 163.2, 163.1, 153.1, 137.8, 
137.7, 132.2, 125.7, 113.8, 112.3, 73.2, 73.0, 66.3, 66.0, 41.9, 38.7, 28.9, 23.6; ESI-MS (m/z) 
calculated for C20H19N5O2F1Cl1I2 [M + H]+: 669.94, found 669.6. 
Compound 21. This compound was synthesized from compound 30 following Path A. Yield: 
25% over three steps. 1H NMR (CD3OD) δ (ppm): 8.35 (s, 1H), 7.59 (s, 2H), 7.34-7.36 (m, 
2H), 5.54-5.56 (m, 1H), 5.21 (s, 1H), 5.12 (s, 1H), 4.32 (s, 1H), 3.37 (t, J = 7.1 Hz, 2H), 2.27-
2.29 (m, 1H), 2.15-2.19 (m, 1H), 1.70-1.83 (m, 1H); 13C NMR (CD3OD) δ (ppm): 168.8, 
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163.1, 160.7, 139.3, 136.6, 124.6, 114.9, 114.1, 92.7, 88.3, 87.2, 84.8, 78.3, 76.9, 41.4, 29.1, 
28.9, 23.7; ESI-MS (m/z) calculated for C22H20N5O2F1I2 [M + H]+: 659.98, found 659.8. 
Compound 22. This compound was synthesized from compound 30 following Path A. Yield: 
20% over three steps. 1H NMR (CD3OD) δ (ppm): 8.36 (s, 1H), 7.59-7.61 (m, 2H), 7.36-7.38 
(m, 2H), 5.54-5.57 (m, 1H), 4.32 (s, 1H), 4.27 (s, 2H), 3.33-3.36 (m, 2H), 2.26-2.33 (m, 1H), 
2.14-2.22 (m, 1H), 1.80-1.85 (m, 1H), 1.72-1.77 (m, 1H); 13C NMR (CD3OD) δ (ppm): 
168.8, 163.4, 160.7, 153.2, 139.3, 136.6, 133.9, 124.8, 114.8, 114.0, 92.7, 88.3, 87.2, 84.8, 
42.0, 38.7, 29.1, 23.6; ESI-MS (m/z) calculated for C22H20N5O2Cl1I2 [M + H]+: 675.95, found 
675.8. 
 
Inactivation kinetics. The rates of enzyme inactivation for compounds 1-22 were determined 
using previously described methods.[3] Briefly, PAD (2 µM for PAD1, 2 and 4; 5 µM for 
PAD3) was added to a prewarmed (10 min at 37 ⁰C) inactivation mixture (100 mM TRIS pH 
7.4, 50 mM NaCl, 10 mM CaCl2, and 2 mM DTT with a final volume of 50 µL) containing 
various concentrations of inhibitors. At various time points, 6 µL of this inactivation mixture 
was removed and was added to a prewarmed (10 min at 37 ⁰C) reaction mixture (100 mM 
TRIS pH 7.4, 50 mM NaCl, 10 mM CaCl2, 2 mM DTT, and 10 mM BAEE (for PAD1, 2 and 
4) or 10 mM BAA (for PAD3) with a final volume of 60 µL). After 15 min, reactions were 
quenched with liquid nitrogen and the production of citrulline was quantified using the 
COLDER assay.[4] The time-dependence of PAD inhibition was fit to the following equation 
1, 
     ν = ν0 e-kt                 (1), 
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using Grafit, version 5.0.11, where ν is velocity, ν0 is initial velocity, k (or kobs is the pseudo-
first-order rate constant of inactivation, and t is time. Upon reaching saturation, the 
concentration dependence of kobs was fit to equation 2, 
    kobs = kinact [I] / (KI + [I])     (2), 
using Grafit, version 5.0.11, where kinact is the maximal rate of inactivation, KI is the 
concentration of inhibitor that affords half-maximal inactivation, and [I] is the concentration 
of inhibitor. When kobs with [I] varied linearly, kinact/KI was determined from the slope of the 
line. All the experiments were performed at least in duplicate. 
RFA labelling. RFA labelling of PAD1 in the presence of inhibitors followed a protocol 
similar to that established for PAD2.[5] Briefly, PAD1 (2 µM final) was added to prewarmed 
(10 min at 37 ⁰C) reaction mixture (100 mM TRIS pH 7.4, 50 mM NaCl, 10 mM CaCl2, and 
2 mM DTT in a final volume of 30 µL) containing RFA (2 µM final) and DMSO or various 
concentrations of the inhibitor. After incubating at 37 ⁰C for 2 h, the reaction mixture was 
quenched with 5X SDS-PAGE loading dye, incubated at 95 ⁰C for 15 min and then loaded 
onto a 10% SDS-PAGE gel. In-gel fluorescence of the protein bands was recorded using a 
typhoon scanner (excitation/emission maxima of ∼546/579, respectively) and was quantified 
using ImageJ software. IC50 values of the inhibitors were obtained by plotting the relative 
decrease in the fluorescence intensity of protein bands against the concentration of inhibitor. 
All the experiments were performed at least in duplicate. 
Determination of log P. Compounds of interest (1 mM) were suspended in a 1:1 mixture of 
n-octanol and 20 mM TRIS-HCl (pH 7.4) (1 mL), and the solvents were constantly mixed on 
an end over end shaker at room temperature for 1h. The emulsion was then centrifuged (8000 
rpm, 1 min) to separate the n-octanol and aqueous layers. The concentration of the compound 
in each layer was determined by LC-MS analysis and the log P values are expressed as the 
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ratio of compound concentration in n-octanol to aqueous layer. All the experiments were 
performed at least in triplicate. 
Preparation and Maintenance of HEK293TPAD1 Cells. The human PADI1 gene was 
amplified from the pET28-PAD1 vector by PCR using the following forward (encoding a 5′ 
KpnI site along with a FLAG tag) and reverse (encoding a 3′ XhoI site) primers. 
Forward primer: 5′-CATGGTACCATGGACTACAAGGACGACGACGACAAGATGGCC 
CCAAAGAGAGTTGT-3′ 
Reverse primer: 5′-GTCTCGAGTCAGGGCACCATGTTCCACCATT-3′ 
The PCR product was purified using a PCR purification kit. The purified PCR product was 
digested with KpnI and XhoI, and the mixture was then run on a 1% agarose gel. The desired 
DNA band was cut from the gel and was extracted using a gel purification kit (Bio Basic 
Canada Inc.). The DNA was then ligated into pcDNA 3.1 Hygro (+), which had also been 
digested with KpnI and XhoI, using T4 DNA ligase.  The ligation mixture was transformed 
into competent E. Coli XL1-Blue cells and penicillin-resistant single colonies were grown by 
culturing at 37 ⁰C for 12 h. pcDNA3.1-PAD1 plasmid was then purified from the cultured 
cells using a plasmid purification kit (Bio Basic Canada Inc.). HEK293T cells (ATCC) were 
grown to 50-60% confluence in Dulbecco's Modified Eagle's Medium (DMEM) 
(supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin and 
100 µg/mL streptomycin) under 5% CO2 atmosphere and were transfected with 20 µg of the 
pcDNA3.1-PAD1 construct using Lipofectamine 2000 according to the manufacturer’s 
protocol.  Cells were further cultured for 48 h post-transfection and then selected with 0.2 
mg/mL hygromycin B to establish stable transfection. Overexpression of PAD1 in 
HEK293TPAD1 cells was confirmed by Western blotting. HEK293TPAD1 cells were 
maintained in DMEM (supplemented with 10% heat-inactivated fetal bovine serum, 100 
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units/mL penicillin, 100 µg/mL streptomycin and 0.15 mg/mL hygromycin B) under 5% CO2 
atmosphere. 
Histone H3 Citrullination in HEK293TPAD1 Cells. HEK293TPAD1 cells were seeded on 
6-well plates at a density of ~1 × 106 cells/well and were allowed to grow in DMEM 
(supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin, 100 
µg/mL streptomycin and 0.15 mg/mL hygromycin B) for 12 h. The monolayer of cells was 
washed gently with 2 mL 1X HBS (140 mM NaCl, 0.7 mM Na2HPO4.2H2O, 20 mM HEPES 
pH 7.4) and each well was filled with 2 mL of 1X HBS (pH 7.4). Then the cells were treated 
with 1 mM CaCl2, 5 µM ionomycin (calcium ionophore) and DMSO or various 
concentrations of inhibitor for 3 h. The final concentration of DMSO in each well was 1%. 
Cells in each well were then collected using a cell scraper, harvested by centrifugation at 
3,000 rpm for 5 min and were resuspended in 1X HBS (100 µL). Triton X-100 (1% final) 
was added to each sample and the cells were lysed using a probe sonicator (pulse amplitude 
of 10 for 10 s, oscillating between 1 s on and 1 s off). Lysates were cleared by centrifugation 
at 21,000g for 15 min and soluble proteins were quantified by DC-assay (Bio-Rad). 2 µg of 
total protein was loaded onto a 4-15% gradient SDS-PAGE gel and separated by 
electrophoresis followed by transferring to a PVDF membrane (Bio-Rad) at 80 V for 50 min. 
The membrane was blocked by treating with 5% BSA in phosphate buffered saline 
supplemented with 0.1% Tween-20 (PBST). The membrane was then treated with mouse 
monoclonal anti-histone H3 (1:1000) and rabbit polyclonal anti-histone H3Cit 2,8,17 
(1:1000) antibodies in blocking solution for 12 h at 4 ⁰C. The membrane was washed with 
PBST (3 times, 10 min for each wash) and was incubated with anti-mouse as well as anti-
rabbit IgG Licor conjugates (1:5000) in PBST and 5% BSA for 1 h at 25 ⁰C. Then the 
membrane was washed with PBST (3 times, 10 min for each wash) and imaged by Licor 
analysis. All the experiments were performed at least in duplicate. 
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Cytotoxicity Studies. HEK293TPAD1 cells were seeded (2 × 104 cells/well) on 96-well 
plate and were allowed to grow in DMEM (supplemented with 10% heat-inactivated fetal 
bovine serum, 100 units/mL penicillin, 100 µg/mL streptomycin and 0.15 mg/mL 
hygromycin B) for 24 h. Cells were then treated with DMSO or various concentrations of 
inhibitor at 37 ⁰C for 24 h. Activated XTT reagent (ATCC) was added to each well and cells 
were further incubated at 37 ⁰C for 5 h. Cell viability was measured by recording the 
absorbance at 475 nm and 660 nm. Equation 3,  
Y = Bottom + (Top-Bottom) / [1 + 10((logEC50-X)*Hillslope)]                (3), 
was used to fit an eight-point dose-response curve to determine the EC50 values for inhibition 
of cell-proliferation using GraphPad Prism 7.03. Top and Bottom are plateaus of the dose-
response curve, X is the log of inhibitor-concentration, Hillslope is the slope factor or Hill 
slope. All the experiments were performed at least in triplicate. 
In Vitro Fertilization. Female ICR mice (4–6 weeks) were injected intraperitoneally with 10 
international units (IU) of pregnant mare serum gonadotropin (PMSG) and after 46 h, 10 IU 
of human chorionicgonadotropin (hCG). After 16 h, cumulus masses were released from 
oviducts into HEPES-buffered HTF culture medium (HTF) (InVitro Care, Frederick, MD). 
Cauda epididymal mouse spermatozoa were released and placed in drops of HTF culture 
medium (InVitro Care). Then the sperm suspensions were added to the cumulus mass drops 
with a final concentration of approximately 1–3 × 105/mL. Zygotes were collected and 
transferred to KSOM medium containing 100 μM PAD1 inhibitor or equal volume of DMSO 





Immunofluorescent and Confocal Microscopy. Embryos were fixed in 4% 
paraformaldehyde in PBS (pH 7.4) for 30 min and then permeabilized in 0.5% Triton X-100 
for 30 min at room temperature. After blocking in 1% BSA/PBS at room temperature for 1 h, 
samples were incubated with anti-H3Cit2/8/17 antibody (Catalogue no. ab77164, Abcam) 
(1:100) at 4 °C for 12 h. After five washes, samples were incubated with FITC-conjugated 
secondary antibody for 1 h at room temperature. Nuclei were counterstained with DAPI for 
5 min. Embryos were mounted on glass slides in a drop of antifade medium (Vectashield, 
Burlingame, CA, USA) and were examined under confocal laser scanning microscope (LSM 
700; Zeiss, Oberkochen, Germany). All the experiments were performed at least in triplicate. 
Dose-dependent in vitro Labelling of Recombinant PADs with 21 and 22. A PAD (1.4 
µM) was added to a prewarmed (10 min at 37 ⁰C) reaction mixture (25 mM TRIS pH 7.4, 10 
mM NaCl, and 5 mM CaCl2) containing various concentrations of 21 or 22 (or equal volume 
of DMSO for control). The mixture was incubated at 37 ⁰C for 15 min. Then TAMRA-N3 (50 
µM), TCEP (1 mM), TBTA (0.3 mM) and freshly prepared copper (II) sulphate (1 mM) were 
sequentially added to the reaction mixture and the tubes were gently tumbled at room 
temperature for 2 h. Then the reactions were quenched with 5X SDS-PAGE loading dye, 
heated at 95 ⁰C for 15 min and loaded onto 4-15% gradient SDS-PAGE gel. Protein bands 
were visualized by recording in-gel fluorescence using a typhoon scanner (approximate 
excitation/emission maxima ~546/579, respectively). All the experiments were performed at 
least in duplicate. 
Limit of Detection for in vitro Labelling of Recombinant PADs with 21 and 22. Various 
concentrations of PAD were added to prewarmed (10 min at 37 ⁰C) reaction mixtures (25 
mM TRIS pH 7.4, 10 mM NaCl, 5 mM CaCl2) containing 10 µM of 21 or 22. The mixture 
was incubated at 37 ⁰C for 15 min followed by sequential addition of TAMRA-N3 (50 µM), 
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TCEP (1 mM), TBTA (0.3 mM) and freshly prepared copper (II) sulphate (1 mM). The tubes 
were then gently tumbled at room temperature for 2 h. Reactions were quenched with 5X 
SDS-PAGE loading dye, heated at 95 ⁰C for 15 min and loaded onto 4-15% gradient SDS-
PAGE gel. Protein bands were visualized by recording in-gel fluorescence using a typhoon 
scanner (approximate excitation/emission maxima ~546/579, respectively). All the 
experiments were performed at least in duplicate. 
Dose-dependent Labelling of PAD1 in HEK293TPAD1 cells with 21. HEK293TPAD1 
cells were plated in 6-well plates at a density of ~1 × 106 cells/well and were allowed to grow 
in DMEM (supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL 
penicillin, 100 µg/mL streptomycin and 0.15 mg/mL hygromycin B) for 12 h. Then the cells 
were washed gently with serum-free DMEM (supplemented with 100 units/mL penicillin and 
100 µg/mL streptomycin) and each well was filled with 2 mL of serum-free DMEM. The 
cells were treated with 1 mM CaCl2, 5 µM ionomycin (calcium ionophore) and DMSO or 
various concentrations of inhibitor for 3 h. Cells were collected using a cell scraper, harvested 
by centrifugation at 3,000 rpm for 5 min and were resuspended in 1X PBS (80 µL). Then the 
cells were lysed using a probe sonicator and lysates were cleared by centrifugation at 21000g 
for 15 min. Soluble proteins in the lysate were quantified by DC-assay (Bio-Rad). Then the 
lysate (1 mg/mL, 50 µL total) was treated with TAMRA-N3 (50 µM), TCEP (1.5 mM), 
TBTA (0.3 mM) and freshly prepared copper (II) sulphate (4 mM). The tubes were then 
gently tumbled at room temperature for 2 h. The precipitated proteins were collected by 
centrifugation at 21000g for 10 min. The protein pellets were resuspended in 5X SDS-PAGE 
loading dye, heated at 95 ⁰C for 15 min and separated by SDS-PAGE. Protein bands were 
visualized by recording in-gel fluorescence using a typhoon scanner (approximate 
excitation/emission maxima ~546/579, respectively). All the experiments were performed at 
least in duplicate. 
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Time-dependent Labelling of PAD1 in HEK293TPAD1 cells with 21. This study followed 
a procedure similar to that described for the dose-dependent labelling of PAD1 in 
HEK293TPAD1 cells with 21. The only difference is that the cells were treated with 1 mM 
CaCl2, 5 µM ionomycin and 5 µM of 21 in serum-free DMEM for various times (0-6 h). At 
various time points, the labelling reaction was quenched by freezing the harvested cells in 
liquid nitrogen. Cells were lysed and lysates were clicked with TAMRA-N3 in the presence 
of TCEP, TBTA and CuSO4 according to the methods described above. Protein bands were 
separated by SDS-PAGE and were visualized by recording in-gel fluorescence. All the 
experiments were performed at least in duplicate. 
Target Engagement Assay - Labelling of PAD1 in HEK293TPAD1 cells with 21 in the 
presence of 1. This study followed a similar procedure to that described for the dose-
dependent labelling of PAD1 in HEK293TPAD1 cells with 21. Briefly, HEK293TPAD1 cells 
were treated with 1 mM CaCl2, 5 µM ionomycin, 5 µM of 21, and increasing concentrations 
(0-50 µM) of 1 in serum-free DMEM for 3 h. Cells were scraped, harvested by centrifugation 
at 3,000 rpm for 5 min and resuspended in 1X PBS. Lysis was carried out by sonicating the 
cells with a probe sonicator and lysates were clicked with TAMRA-N3 in the presence of 
TCEP, TBTA and CuSO4 as described above. Protein bands were separated by SDS-PAGE 
and were visualized by recording in-gel fluorescence. Fluorescence intensities of the protein 
bands were quantified by ImageJ software and were plotted against the concentration of 1 to 
afford the EC50 value. All the experiments were performed at least in duplicate. 
Enrichment of Proteins Labelled by 21 in HEK293TPAD1 Cells on Streptavidin-
agarose. HEK293TPAD1 cells were cultured in 175 cm2 T-175 flasks in DMEM 
(supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin, 100 
µg/mL streptomycin and 0.15 mg/mL hygromycin B). Upon reaching ~90% confluence, cells 
were treated with 1 mM CaCl2, 5 µM ionomycin and 5 µM of 21 (or equal volume of DMSO 
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for control) in serum-free DMEM for 3 h. Then the cells were scraped, harvested by 
centrifugation at 3,000 rpm for 5 min and resuspended in 1X PBS. Cell lysis was performed 
by probe sonication and soluble proteins in the lysates were quantified by DC Assay (Bio-
Rad). Endogenous biotinylated proteins were precleared by incubating the lysates with 
streptavidin-agarose beads (25 µL for 1 mg of total protein in the lysate) at room temperature 
for 1 h with constant mixing on an end-over-end shaker. The mixture was centrifuged (1200 
g, 3 minute) to separate the beads and the supernatant (pre-cleared lysate).  Pre-cleared 
lysates (2 mg/mL, 500 µL final) were clicked with Biotin-N3 (100 µM), TCEP (1.5 mM), 
TBTA (0.3 mM) and freshly prepared CuSO4 (4 mM), and the tubes were gently tumbled at 
room temperature for 2 h. The precipitated proteins were collected by centrifugation at 5,000 
rpm for 10 min. The protein pellets were washed with ice-cold methanol, dried at room 
temperature for 5 min and resuspended in 1.2% SDS in PBS. SDS-solubilized proteins were 
then diluted with PBS to a final SDS concentration of 0.2% and were incubated with 
streptavidin-agarose beads (170 µL for 2 mg of total protein) at 4 ⁰C for 16 h on an end-over-
end shaker. The solutions were then incubated at room temperature for 3 h. The streptavidin 
beads were collected by centrifugation at 1200g for 3 min and were washed with 2 M urea (2 
× 5 mL), 0.2% SDS in PBS (2 × 5 mL), PBS (3 × 5 mL) and water (3 × 5 mL). The beads 
were pelleted by centrifugation at 1200g for 3 min between washes. The washed beads were 
resuspended in 6 M urea (500 µL) and were treated with dithiothreitol (10 mM) at 65 ⁰C for 
20 min. Iodoacetamide (20 mM final) was then added to the mixture and the beads were 
further incubated at 37 ⁰C for 30 min. The beads were collected by centrifugation at 1200g 
for 3 min and were treated with a premixed solution of 2 M urea in PBS (200 µL), 100 mM 
CaCl2 (2 µL) and trypsin (4 µL of 20 µg reconstituted in 40 µL of trypsin buffer) at 37 ⁰C for 
12 h. The digested peptides were separated from the beads by centrifugation and the beads 
were washed twice with water (50 µL). The digest was then desalted using a Pierce C18 spin 
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column (catalogue no 89870) according to the manufacturer’ protocol and resuspended in 100 
µL 100 mM triethylammonium bicarbonate pH 8.5. 4 µL of 20% D13CDO (heavy 
formaldehyde) and 2.5 µL of 37% HCHO (light formaldehyde) were added to the 21-treated 
and control samples, respectively. 20 µL of 0.6 M sodium cyanoborohydride was then added 
to both the 21-treated and control samples, and the samples were incubated at room 
temperature for 2 h. The samples were cooled on ice and the reaction quenched with 4 µL of 
20% ammonium hydroxide. 8 µL of formic acid was then added to the samples. Heavy (21-
treated) and light (control) samples were mixed together and were stored at -20 ⁰C for 
proteomic analysis. All the experiments were performed at least in duplicate. 
Proteomic Analysis and Data Processing. Mass Spectrometry was performed using a 
Thermo Fisher LTQ Orbitrap Discovery mass spectrometer in conjunction with an Agilent 
1200 series HPLC.  Labeled peptide samples were pressure-loaded onto a 250 m fused silica 
desalting column packed with 4 cm of Aqua C18 reverse phase resin (Phenomenex).  
Peptides were eluted onto a biphasic 100 m fused silica column with a 5 m tip packed with 
4 cm Partisphere strong cation exchange resin (SCX, Whatman) followed by 10 cm of C18 
resin.  The peptides were separated from the SCX onto the C18 resin using 5 distinct salt 
pulses (95% high-purity water, 5% Optima-grade acetonitrile, 0.1% formic acid and 500 mM 
ammonium acetate) as outlined in Weerapana et. al.[6]  C18 elution took place using a 
gradient from 5% Buffer A (95% water, 5% acetonitrile, 0.1% formic acid), to 100% Buffer 
B (20% water, 80% acetonitrile, 0.1% formic acid).  The flow rate through the column was 
0.25 mL/min, with a spray voltage of 2.75 kV. With dynamic exclusion enabled, each full 




 The tandem MS data was analyzed by the SEQUEST algorithm[7] using a static Cys 
modification (+57 Da), and a static modification on Lys and the N-termini of either +28 Da 
(light) or +34 Da (heavy).  Data was searched against a human reverse-concatenated non-
redundant FASTA database applying Uniprot identifiers. MS2 spectra were assembled using 
DTASelect 2.0,[8] with the –trypstat option applied. Quantification of Heavy/Light ratios were 
calculated using the Cimage quantification package.[9]  Ratios across peptides were averaged 























Table S1. kinact/KI values and selectivity of compounds 1-22 for inhibition of PAD1-4. 
Compound kinact/KI (M-1min-1) [Fold PAD selectivity] 
PAD1 PAD2 PAD3 PAD4 
1 10400 ± 2380* 
[74] 
140 ± 20† 
[1] 
200 ± 40† 
[1] 
270 ± 40† 
[2] 
2 58860 ± 3640* 
[19] 
8110 ± 1020* 
[3] 
3050 ± 1150*  
[1] 
11060 ± 2880* 
[4] 
3 5870 ± 790* 
[8] 
1650 ± 70† 
[2] 
2160 ± 80† 
[3] 
750 ± 70† 
[1] 
4 66020 ± 2870* 
[15] 
9730 ± 2210* 
[2] 
4400 ± 140‡ 
[1] 
24110 ± 90* 
[5] 
5 7280 ± 960* 
[9] 
770 ± 80† 
[1] 
2470 ± 260† 
[3] 
1070 ± 180† 
[1] 
6 59480 ± 14000* 
[18] 
3230 ± 790† 
[1] 
3300 ± 70‡ 
[1] 
35190 ± 4970* 
[11] 
7 120 ± 20† 
[1] 
120 ± 20† 
[1] 
1620 ± 360*  
[14] 
2530 ± 200* 
[21] 
8 600 ± 70‡ 
[1] 
2800 ± 210‡ 
[5] 
10590 ± 3980† 
[18] 
41040 ± 630* 
[68] 
9 190 ± 20† 
[1] 
400 ± 30† 
[2] 
580 ± 120† 
[3] 
240 ± 20† 
[1] 
10 5080 ± 210* 
[1] 
4190 ± 900* 
[1] 
10060 ± 1850* 
[2] 
9690 ± 480* 
[2] 
11 3280 ± 210* 
[25] 
130 ± 10† 
[1] 
420 ± 30† 
[3] 
250 ± 20† 
[2] 
12 40740 ± 2960* 
[3] 
14210 ± 110* 
[1] 
21560 ± 2430* 
[2] 
18810 ± 970* 
[1] 
13 1290 ± 90* 
[10] 
130 ± 20† 
[1] 
550 ± 40† 
[4] 
290 ± 10† 
[2] 
14 5300 ± 210‡ 
[2] 
3400 ± 70‡ 
[1] 
5500 ± 300‡ 
[2] 
2600 ± 70‡ 
[1] 
15 1500 ± 30* 
[13] 
120 ± 30† 
[1] 
500 ± 50† 
[4] 
640 ± 90† 
[5] 
16 3900 ± 100‡ 
[2] 
1700 ± 70‡ 
[1] 
5000 ± 280‡ 
[3] 
3600 ± 70‡ 
[2] 
17 300 ± 30† 
[3] 
110 ± 10† 
[1] 
240 ± 30† 
[2] 
180 ± 20† 
[2] 
18 4100 ± 300‡ 
[4] 
2210 ± 270† 
[2] 
1170 ± 40† 
[1] 
3160 ± 550† 
[3] 
19 13250 ± 2870* 
[44] 
300 ± 60† 
[1] 
700 ± 70† 
[2] 
300 ± 30† 
[1] 
20 94360 ± 14870* 
[4] 
34290 ± 1970* 
[1] 
70000 ± 15000* 
[3] 
24310 ± 1060* 
[1] 
21 4480 ± 200* 
[34] 
130 ± 30† 
[1] 
310 ± 80† 
[2] 
220 ± 30† 
[2] 
22 72160 ± 10970* 
[9] 
31230 ± 1440* 
[4] 
8200 ± 30* 
[1] 
25000 ± 1370* 
[3] 
*kinact and KI were determined from a nonlinear fit of the kobs versus [I] data. ‡kinact/KI was 




Table S2. kinact and KI values of inhibition of PAD1-4 by compounds 1-22. 
Compounds 








































































































































NA† NA† NA† NA† NA† NA† 






NA† NA† NA† NA† NA† NA† 
16 NA‡ NA‡ NA‡ NA‡ NA‡ NA‡ NA‡ NA‡ 
17 NA† NA† NA† NA† NA† NA† NA† NA† 















































NA: Not applicable. †A single kobs was determined to calculate kinact/KI. ‡kinact/KI was determined from a 








1 4.76 3.89 ± 0.07 
19 4.92 3.59 ± 0.22 
11 3.71 1.95 ± 0.06 
13 3.44 1.89 ± 0.01 
7 2.30 0.87 ± 0.06 









Figure S1. Inhibition of PAD1 by compounds 1-22. 1 (A), 2 (B), 3 (C), 4 (D), 5 (E), 6 (F), 7 
(G), 8 (H), 9 (I), 10 (J), 11 (K), 12 (L), 13 (M), 14 (N), 15 (O), 16 (P), 17 (Q), 18 (R), 19 (S), 









Figure S2. Inhibition of PAD2 by compounds 1-22. 1 (A), 2 (B), 3 (C), 4 (D), 5 (E), 6 (F), 7 
(G), 8 (H), 9 (I), 10 (J), 11 (K), 12 (L), 13 (M), 14 (N), 15 (O), 16 (P), 17 (Q), 18 (R), 19 (S), 














Figure S3. Inhibition of PAD3 by compounds 1-22. 1 (A), 2 (B), 3 (C), 4 (D), 5 (E), 6 (F), 7 
(G), 8 (H), 9 (I), 10 (J), 11 (K), 12 (L), 13 (M), 14 (N), 15 (O), 16 (P), 17 (Q), 18 (R), 19 (S), 











Figure S4. Inhibition of PAD4 by compounds 1-22. 1 (A), 2 (B), 3 (C), 4 (D), 5 (E), 6 (F), 7 
(G), 8 (H), 9 (I), 10 (J), 11 (K), 12 (L), 13 (M), 14 (N), 15 (O), 16 (P), 17 (Q), 18 (R), 19 (S), 










Figure S5. (A) Labelling of PAD1 by RFA in the presence of compounds 2, 12, 14 and 8. I, F 
and C refers to the inhibitor, fluorograph and coomassie stain, respectively. (B) 




















Figure S6. Overexpression of PAD1 in HEK293TPAD1 cells as detected by Western blot 
analysis of the cell lysates using anti-FLAG (α-DYKDDDDK) (A) and anti-PAD1 (B) 













Figure S7. (A) Histone H3 citrullination in HEK293T cell lysates spiked with various 
concentrations of PAD1 and PAD2. Assay conditions: Lysate (2 mg/mL), PAD (desired 
concentration), 100 mM TRIS, 50 mM NaCl, 10 mM CaCl2, pH 7.4, 37 ⁰C, 3 h. PAD2 was 
used as a positive control. (B) Histone H3 citrullination in HEK293TPAD1 cells in the 
presence of calcium and plus/minus a calcium ionophore, ionomycin (I). All the experiments 




Figure S8. Inhibition of histone H3 citrullination in HEK293TPAD1 cells by compounds 2 
(A) and 20 (B). I refers to the inhibitor concentrations in µM. Quantification of each band 
yielded the H3Cit/H3 ratio, from which % relative H3 citrullination was calculated. Cells 
were treated with various concentrations of inhibitor in the presence of 1 mM CaCl2 and 5 




Figure S9. Inhibition of cell-proliferation of HEK293TPAD1 cells by compounds 1 (A), 2 
(B), 7 (C), 11 (D), 13 (E), 19 (F), 20 (G), 21 (H) and BB-Cl-amidine (I). The EC50 values are 
listed in the table (J). Potency refers to the efficiency of these compounds to inhibit histone 
H3 citrullination in HEK293TPAD1 cells. Comparison of the EC50 values for cytotoxicity 
and potency (efficacy index) indicates that these compounds inhibit histone H3 citrullination 




Figure S10. Quantification of inhibition of histone H3 citrullination in mice embryos by 1 
and 19.  Mouse embryos (4-cell) cultured with DMSO (control), 1 or 19 (100 µM) were 
incubated with anti-histone H3Cit2/8/17 and DAPI as immunofluorescence staining agents 
for citrullinated histone H3 and DNA, respectively. Both 1 and 19 significantly inhibit 




Figure S11. (A) Dose-dependent in vitro labelling of PADs by compound 22. (B) Limit of 
detection of PADs by compound 22. 1.4 µM of PAD and 10 µM of 22 were used for the 
dose-dependence and limit of detection studies, respectively. F and C refer to fluorograph and 




Figure S12. (A) Time-dependent labelling of PAD1 in HEK293TPAD1 cells by 21. 
HEK293TPAD1 cells were treated with 21 (5 µM) in serum-free DMEM for various times. 
After the treatment, cells were harvested and flash-frozen in liquid nitrogen. Cell lysates were 
treated with TAMRA-N3, TCEP, TBTA and CuSO4 for 2 h at room temperature. Time-
dependent labelling of PAD1 by 21 was recorded on a Typhoon scanner. (B) Limit of 
detection of PAD1 in HEK293TPAD1 cells by 21. For this study, cells were treated with 5 
µM of 21 in serum-free DMEM for 3 h and decreasing amounts (indicated by total protein 
content) of lysates were clicked with TAMRA-N3 in the presence of TCEP, TBTA and 
freshly prepared CuSO4. PAD1 content in HEK293TPAD1 cells was found to be 0.06% of 
the total protein and taking this into account, limit of detection of PAD1 in HEK293TPAD1 




Figure S13. (A) Pull-down of PAD1 in HEK293TPAD1 cells on Streptavidin-agarose beads 
using 21 and Biotin-N3. HEK293TPAD1 cells were treated with 5 µM 21 in the presence of 1 
mM CaCl2 and 5 µM ionomycin at 37 ⁰C for 3 h, and the labelled proteins were clicked with 
Biotin-N3 in the presence of TCEP, TBTA and CuSO4. Biotinylated proteins were then 
selectively captured on Streptavidin-agarose beads and were eluted by heating the beads in a 
mixture of 4 M urea, 15 mM biotin and 2.5X SDS-PAGE loading dye at 95 ⁰C for 30 min. 
The input and elution were analyzed by western blot using streptavidin-800. (B) 
Representative isotopic comparison of peptides from GAPDH and PAD1 obtained by trypsin 
digestion of the pulled-down proteins from HEK293TPAD1 cells by 21. 21-treated and 
control samples were labelled with heavy (blue) and light (red) formaldehyde, respectively. 
GAPDH shows a ratio close to 1 (i.e. no change), while PAD1 shows a strong enrichment 
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